Effects of CYP2C9 and MDR1 polymorphism on the pharmacokinetics of losartan

被引：0
|
作者：
Bae, Jung-Woo
Han, Ho-Kyun
Lee, Hwan-Joo
Jung, Dong -Won
Kim, Nam-Tae
Lee, Jin-Hee
Jang, Choon-Gon
Choi, Sun-Ok
Kim, Ok-Hee
Lee, Seok-Yong
机构：
[1] Sungkyunkwan Univ, Coll Pharm, Seoul, South Korea
[2] Natl Inst Toxicol Res, Seoul, South Korea
来源：
ACTA PHARMACOLOGICA SINICA | 2006年 / 27卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：230 / 231
页数：2
相关论文
共 50 条
  • [21] Effects of genetic polymorphism of CYP2C9 on the pharmacokinetics of lornoxicam in healthy Korean subjects.
    Bac, J.
    Kim, N.
    Lee, H.
    Lee, J.
    Jung, D.
    Kim, M.
    Jang, C.
    Lee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S33 - S34
  • [22] Effects of CYP2C9 polymorphism on the pharmacokinetics and pharmacodynamics of meloxicam in healthy korean subjects.
    Bae, J.
    Kim, M.
    Song, Y.
    Sa, J.
    Choi, C.
    Jang, C.
    Lee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S31 - S31
  • [23] Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
    M Wadelius
    K Sörlin
    O Wallerman
    J Karlsson
    Q-Y Yue
    P K E Magnusson
    C Wadelius
    H Melhus
    The Pharmacogenomics Journal, 2004, 4 : 40 - 48
  • [24] Prediction of the Effects of Genetic Polymorphism on the Pharmacokinetics of CYP2C9 Substrates from In Vitro Data
    Makiko Kusama
    Kazuya Maeda
    Koji Chiba
    Akinori Aoyama
    Yuichi Sugiyama
    Pharmaceutical Research, 2009, 26
  • [25] Prediction of the Effects of Genetic Polymorphism on the Pharmacokinetics of CYP2C9 Substrates from In Vitro Data
    Kusama, Makiko
    Maeda, Kazuya
    Chiba, Koji
    Aoyama, Akinori
    Sugiyama, Yuichi
    PHARMACEUTICAL RESEARCH, 2009, 26 (04) : 822 - 835
  • [26] Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast
    Hyun-Jee Lee
    Young-Hoon Kim
    Se-Hyung Kim
    Choong-Min Lee
    Ae-Yun Yang
    Choon-Gon Jang
    Seok-Yong Lee
    Jung-Woo Bae
    Chang-Ik Choi
    Archives of Pharmacal Research, 2016, 39 : 1013 - 1019
  • [27] Effects of CYP2C9*13 allele on the pharmacokinetics of Irbesartan
    Lim, Hye-Jin
    Kim, Dong-Hyun
    Byeon, Ji-Yeong
    Kim, Young-Hoon
    Kim, Se-Hyung
    PHARMACOTHERAPY, 2015, 35 (11): : E315 - E316
  • [28] EFFECTS OF CYP2C9☆13 ALLELE ON THE PHARMACOKINETICS OF IRBESARTAN
    Park, J., I
    Choi, C., I
    Bae, J. W.
    Jang, C. G.
    Lee, S. Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 64 - 64
  • [29] Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast
    Lee, Hyun-Jee
    Kim, Young-Hoon
    Kim, Se-Hyung
    Lee, Choong-Min
    Yang, Ae-Yun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Bae, Jung-Woo
    Choi, Chang-Ik
    ARCHIVES OF PHARMACAL RESEARCH, 2016, 39 (07) : 1013 - 1019
  • [30] CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population
    Allabi, AC
    Gala, JL
    Horsmans, Y
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (11): : 779 - 786
12345